A new letter from Senator Jim Banks to Acting FDA Commissioner Kyle Diamantas may offer the clearest indication yet of where the next phase of GLP-1 enforcement is headed. The Indiana Republican is asking the FDA to investigate Hims & Hers and potentially other telehealth companies over advertising claims, pricing practices, and the marketing of compounded GLP-1 medications. While the headlines focus on a single company, the broader significance lies in the questions Banks believes regulators should be asking across the industry.